New IVIG aims to slash infection risk for immune-deficient patients
NCT ID NCT06150833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called Boya IVIG in 50 people with primary immunodeficiency (CVID or XLA), a condition where the body can't fight infections well. Participants get the drug every 21 or 28 days for a year to see if it keeps serious bacterial infections below one per year. The goal is to replace missing antibodies and help the immune system work better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody infusion shows promise for immune deficiency patients
- Breathing test could help doctors personalize antibody therapy for immune deficiency
- Gentler transplant shows promise for kids with blood diseases
- Can a simple ultrasound spot hidden liver danger in immune disorder patients?
- Can a new immune system fix T-Cell diseases? trial tests donor transplants
- Milder stem cell transplant shows promise for kids with immune disorders